Most importantly, the nanohybrid was able to successfully deliver EGCG into cancer cells, displaying impressive protein kinase CK2 inhibition comparable to that obtained with the most specific CK2 inhibitor, CX-4945 (5.5 vs. 3 μM), thus promoting the phytochemical exploitation as a valuable alternative for cancer therapy. This evidence concerns the gene WEE1 and cancer.